POPULATION PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN, AN ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH CD30-POSITIVE HEMATOLOGIC MALIGNANCIES.

被引：0
|
作者：
Li, H. [1 ]
Han, T. H. [2 ]
Hunder, N. [1 ]
Jang, G. [1 ]
Zhao, B. [1 ]
机构：
[1] Seattle Genet, Bothell, WA USA
[2] Stemcentrx Inc, San Francisco, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-041
引用
收藏
页码：S41 / S42
页数：2
相关论文
共 50 条
  • [1] EFFECT OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN, AN ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH CD30-POSITIVE HEMATOLOGIC MALIGNANCIES
    Han, T. H.
    Grove, L. E.
    Lynch, C. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S17 - S18
  • [2] Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment
    Zhao, Baiteng
    Chen, Robert
    O'Connor, Owen A.
    Gopal, Ajay K.
    Ramchandren, Radhakrishnan
    Goy, Andre
    Matous, Jeffrey V.
    Fasanmade, Adedigbo A.
    Manley, Thomas J.
    Han, Tae H.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (03) : 696 - 705
  • [3] Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies
    Gualberto, Antonio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (02) : 205 - 216
  • [4] Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
    Nancy L Bartlett
    Robert Chen
    Michelle A Fanale
    Pauline Brice
    Ajay Gopal
    Scott E Smith
    Ranjana Advani
    Jeffrey V Matous
    Radhakrishnan Ramchandren
    Joseph D Rosenblatt
    Dirk Huebner
    Pamela Levine
    Laurie Grove
    Andres Forero-Torres
    Journal of Hematology & Oncology, 7
  • [5] Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
    Bartlett, Nancy L.
    Chen, Robert
    Fanale, Michelle A.
    Brice, Pauline
    Gopal, Ajay
    Smith, Scott E.
    Advani, Ranjana
    Matous, Jeffrey V.
    Ramchandren, Radhakrishnan
    Rosenblatt, Joseph D.
    Huebner, Dirk
    Levine, Pamela
    Grove, Laurie
    Forero-Torres, Andres
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [6] CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody-Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies
    Han, Tae H.
    Gopal, Ajay K.
    Ramchandren, Radhakrishnan
    Goy, Andre
    Chen, Robert
    Matous, Jeffrey V.
    Cooper, Maureen
    Grove, Laurie E.
    Alley, Stephen C.
    Lynch, Carmel M.
    O'Connor, Owen A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (08): : 866 - 877
  • [7] THE PHARMACOKINETICS OF BRENTUXIMAB VEDOTIN (SGN-35), AN ANTIBODY-DRUG CONJUGATE (ADC).
    Han, T. H.
    Kennedy, D.
    Hayes, S.
    Lynch, C. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S51 - S51
  • [8] Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies
    Li, Hong
    Han, Tae H.
    Hunder, Naomi N.
    Jang, Graham
    Zhao, Baiteng
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (09): : 1148 - 1158
  • [9] Brentuximab vedotin: An anti-CD30 antibody-drug conjugate
    Bradley, Amber M.
    Devine, Meghan
    DeRemer, David
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (07) : 589 - 597
  • [10] CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
    Lobastova, Liudmila
    Lettau, Marcus
    Babatz, Felix
    de Oliveira, Thais Dolzany
    Nguyen, Phuong-Hien
    Pauletti, Bianca Alves
    Schauss, Astrid C.
    Duerkop, Horst
    Janssen, Ottmar
    Leme, Adriana F. Paes
    Hallek, Michael
    Hansen, Hinrich P.
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
12345